- To outline the outcomes of past NPT research
- To outline the status of ongoing and upcoming NPT research
- To highlight key social and behavioural research questions related to NPTs
- To highlight issues related to access of NPTs
- Slide 3: Facilitator should elaborate on trials he/she feels most comfortable explaining.
- So far, only medical male circumcision (in the case of HIV‐negative men having vaginal intercourse with HIV‐positive women), the AIDSVAX/ALVAC vaccine combination, tenofovir gel used vaginally (through the CAPRISA 004 trial), and once daily oral Truvada for men who have sex with men (through the iPrEx trial) have shown signs of efficacy in reducing the risk of HIV transmission.
- Between 2011 and 2013, several late‐stage clinical trials in the HIV prevention field are expected to produce results. Most of these trials are testing ARV‐based prevention methods.
- Small biotech companies, universities, government agencies, and non‐profit entities are doing the research and are being funded by governments and private foundations. Trials are not moving forward as rapidly as they could because they are delayed due to lack of money.
- NOTE: Should update slides 5‐8 as current clinical trials end and late stage trials begin.
Key considerations (slide 19)
Modify the populations listed on this slide to be most relevant for your national context, and have participants identify the key considerations to keep in mind when thinking about access to NPTs for each of the populations.